aav2-gdnf
Gene therapyexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 29, 2012 (NCT01621581)
Timeline
Indications
Mechanism of action
- GDNF family receptor alpha-1Supplementation
GFRA1 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- aav2-gdnf
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06285643 | Phase 2 | Jun 11, 2024 | Asklepios BIoPharmaceutical, Bayer |
| NCT04680065 | Phase 1 | Nov 30, 2021 | Brain Neurotherapy Bio, Inc. |
| NCT04167540 | Phase 1 | Nov 30, 2019 | Brain Neurotherapy Bio, Inc. |
| NCT01621581 | Phase 1 | May 29, 2012 | National Institute of Neurological Disorders and Stroke (NINDS) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Brain Neurotherapy Bio, Inc. | For profit | 2 | 2 | 1 | 2019 |
| Asklepios BIoPharmaceutical | For profit | 1 | 1 | 1 | 2024 |
| Bayer | For profit | 1 | 0 | 1 | 2024 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 1 | 1 | 2012 |
4 organizations
Page 1 / 1